Get the Stockscreener App
16.75
0.36%
0.06
Bicara Therapeutics Inc stock is traded at $16.75, with a volume of 463.51K.
It is up +0.36% in the last 24 hours and down -7.71% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$16.69
Open:
$16.66
24h Volume:
463.51K
Relative Volume:
0.69
Market Cap:
$917.60M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.69%
1M Performance:
-7.71%
6M Performance:
+55.24%
1Y Performance:
+40.99%
1-Day Range:
$16.54
$17.16
1-Week Range:
$16.45
$18.05
52-Week Range:
$7.80
$19.71
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
16.75 | 914.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Initiated | BTIG Research | Buy |
| Dec-18-25 | Initiated | Mizuho | Neutral |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
BCAX: De-Risked FORTIFI-HN01 Path, Differentiated Ficera Profile, and Solid Cash Runway Underpin Buy Rating and $28 Target - TipRanks
Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress - Investing.com Nigeria
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), NewAmsterdam Pharma Company (NAMS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
Does Bicara Therapeutics Inc align with a passive investing strategyDividend Hike & Weekly Market Pulse Updates - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Bicara Therapeutics stock - Investing.com
How cyclical is Bicara Therapeutics Inc.’s revenue stream2025 Market Outlook & Daily Growth Stock Investment Tips - bollywoodhelpline.com
Bicara Therapeutics (NASDAQ:BCAX) Given Outperform Rating at Wedbush - Defense World
Growth Report: Will Bicara Therapeutics Inc. stock continue upward momentumJuly 2025 Opening Moves & Weekly Breakout Watchlists - Bộ Nội Vụ
Wedbush Reaffirms Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Bicara selects optimal dose for head and neck cancer drug in pivotal study - Investing.com Nigeria
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 7%Time to Sell? - MarketBeat
Bicara Sets Phase 3 Path for Ficerafusp Alfa - TipRanks
Bicara Therapeutics announces phase 3 optimal dose and provides 2026 corporate outlook - marketscreener.com
Bicara Therapeutics Inc Announces Phase 3 Optimal Dose and 2026 Outlook - TradingView — Track All Markets
Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook - TradingView — Track All Markets
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook - GlobeNewswire
Published on: 2026-01-12 06:24:33 - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Trading 7.8% Higher – Should You Buy? - Defense World
Is Bicara Therapeutics Inc. stock trading at a premium valuationWeekly Trade Review & Precise Trade Entry Recommendations - ulpravda.ru
BTIG Research Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc.Common Stock (NQ: BCAX - FinancialContent
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.8%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at BTIG Research - MarketBeat
Published on: 2026-01-09 02:43:58 - Улправда
Is Bicara Therapeutics Inc. stock a defensive play in 2025July 2025 Breakouts & Safe Entry Trade Signal Reports - Улправда
Bicara Therapeutics Inc. (BCAX) Stock Analysis: Unveiling an 83.84% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Upcoming EventsBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Detailed Stock Data - FinancialContent
BTIG Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - Nasdaq
Los Angeles Daily NewsBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Price Chart - FinancialContent
History Review: Can Bicara Therapeutics Inc. stock deliver sustainable ROEMarket Risk Summary & Real-Time Market Sentiment Reports - ulpravda.ru
What hedge fund activity signals for Bicara Therapeutics Inc. stockQuarterly Profit Summary & AI Based Trade Execution Alerts - Улправда
Bicara Therapeutics initiated with a Buy at BTIG - TipRanks
BTIG initiates coverage on Bicara Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
BTIG Research Initiates Coverage on Bicara Therapeutics With Buy Rating, $28 Price Target - MarketScreener
BTIG initiates coverage on Bicara Therapeutics stock with Buy rating - Investing.com
News | postregister.comBicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Stock Quote - FinancialContent
Can Bicara Therapeutics Inc. stock rebound after recent weaknessEarnings Date Calendar & Free Grow Wealth With Picks - Улправда
Bicara Therapeutics: How InvestingPro’s overvaluation call led to 39% decline By Investing.com - Investing.com South Africa
Bicara Therapeutics management to meet with Cantor Fitzgerald - MSN
Will Bicara Therapeutics Inc. stock continue dividend increases2026 world cup usa national team group stage playmakers pressing system winner prediction preview - Улправда
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Hold” from Analysts - Defense World
What Drawdown Risk Means for Long Term Holders of Clean Science and Technology LimitedStock Buyback Announcements & Zero-Cost Stock Research by Professionals - earlytimes.in
Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - MSN
Bicara Therapeutics (NASDAQ:BCAX) Trading 3.9% Higher – Here’s Why - Defense World
Aug Chart Watch: What hedge fund activity signals for Bicara Therapeutics Inc stockWeekly Market Outlook & Daily Profit Maximizing Tips - moha.gov.vn
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 3.9%Still a Buy? - MarketBeat
Straddle Buy Call Buy Put at same strikeEarnings Call Summaries & Exceptional Return Growth - bollywoodhelpline.com
Hyep Ivan, Bicara Therapeutics CFO, sells $168k in BCAX stock - Investing.com India
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cohlhepp Ryan | President and COO |
Dec 26 '25 |
Option Exercise |
4.44 |
25,000 |
110,922 |
214,141 |
| Raben David | Chief Medical Officer |
Dec 26 '25 |
Option Exercise |
3.79 |
19,789 |
74,996 |
55,286 |
| Hyep Ivan | Chief Financial Officer |
Dec 22 '25 |
Option Exercise |
3.79 |
9,200 |
34,866 |
154,555 |
| Hyep Ivan | Chief Financial Officer |
Dec 22 '25 |
Sale |
18.31 |
9,200 |
168,492 |
145,355 |
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):